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Abstract
Background Lymph node metastases are a major prognostic indicator in oesophageal cancer. Radiological staging largely 
inluences treatment decisions and is becoming more reliant on PET and CT. However, the sensitivity of these modalities is 
suboptimal and is known to under-stage disease. The primary aim of this study was to validate a published prognostic model 
in oesophageal cancer patients staged N0 with PET/CT, which showed that EUS nodal status was an independent predictor of 
survival. The secondary aim was to assess the prognostic signiicance of pathological lymph node metastases in this cohort.
Methods An independent validation cohort included 139 consecutive patients from a regional upper gastrointestinal cancer 
network staged N0 with PET/CT between 1st January 2013 and 31st June 2015. Replicating the original study, two Cox 
regression models were produced: one included EUS T-stage and EUS N-stage, and one included EUS T-stage and EUS 
N0 versus N+. The primary outcome of the prognostic model was overall survival (OS). Kaplan–Meier analysis assessed 
diferences in OS between pathological node-negative (pN0) and node-positive (pN+) groups. A p value of < 0.05 was 
considered statistically signiicant.
Results The mean OS of the validation cohort was 29.8 months (95% CI 27.1–35.2). EUS T-stage was signiicantly and 
independently associated with OS in both models (p = 0.011 and p = 0.012, respectively). EUS N-stage and EUS N0 versus 
N+ were not signiicantly associated with OS (p = 0.553 and p = 0.359, respectively). There was a signiicant diference in 
OS between pN0 and pN+ groups (χ2 13.315, df 1, p < 0.001).
Conclusion Lymph node metastases have a signiicant detrimental efect on OS. This validation study did not replicate the 
results of the developed prognostic model but the continued beneit of EUS in patients staged N0 with PET/CT was demon-
strated. EUS remains a valuable component of a multi-modality approach to oesophageal cancer staging.
Keywords Oesophageal cancer · Endoscopic ultrasound · Positron-emission tomography · Prognosis · Survival
In oesophageal cancer, clinical management is largely inlu-
enced by radiological lymph node staging. Accurate radio-
logical staging is therefore vital to guide optimum treatment 
decisions for each patient. Patients considered to have lymph 
node metastases are more likely to receive neo-adjuvant 
therapy prior to surgery, routinely involving a combination 
of chemotherapy and radiotherapy [1].
Under-staging of lymph node metastases increases the 
likelihood of recurrence and has a negative impact upon 
overall survival (OS) [2]. Under-staging of disease can also 
impact on patient’s quality of life, potentially exposing them 
to high-risk surgical resection or deinitive chemo-radiother-
apy with toxic side-efects [3]. Currently, patients consid-
ered to be suitable for radical therapy undergo PET/CT and 
EUS for further detailed assessment of local and distant dis-
ease [4]. However, EUS utilisation in the UK is declining. 
Data from the National Oesophago-Gastric Cancer Audit 
(NOGCA) show 47.5% of patients had staging EUS in 2016 
compared to 62% in 2013 [5].
As a result, there is an increasing reliance on cross-sec-
tional imaging for treatment planning. The low sensitivity of 
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PET/CT can increase the false-negative diagnostic rate for 
lymph node metastases, under-staging regional disease and 
contributing to suboptimal treatment decisions [6].
A prognostic model investigating the additional role of 
EUS in patients staged N0 on PET/CT was developed [7]. 
The results of the study showed a signiicant diference in 
OS in patients with EUS-positive nodal disease compared 
to EUS N0 disease. The inherently poor spatial resolution 
of PET was thought to afect the diferentiation of peri-
tumoural nodes and the detection of small lymph node 
metastases, compared to the superior spatial resolution of 
EUS [8].
The primary aim of this study was to validate the prog-
nostic model in an independent cohort of oesophageal cancer 
patients staged N0 with PET/CT. The secondary aim was 
to assess the prognostic signiicance of pathological lymph 
node metastases in these patients.
Materials and methods
This was a validation study of a previously published prog-
nostic model [7]. The setting was a regional upper gastroin-
testinal cancer network serving a population of 1.5 million. 
The prognostic model was developed in patients staged with 
PET/CT in two centres (sites 1 and 2). Validation was con-
ducted in an independent cohort of patients staged N0 with 
PET/CT in site 2 only. Scientiic review by the Research 
Review Board was performed and institutional research 
approval was obtained (reference 13//DMD5769). Formal 
ethical approval was not required for this study.
Development and validation cohorts
One-hundred and seventeen patients were included in the 
development patient cohort. Consecutive patients were 
staged N0 with PET/CT between 1st December 2008 and 
31st May 2012. PET/CT examinations were performed 
across 2 sites; 47 in the irst centre (site 1) and 70 in the 
second centre (site 2). The PET/CT protocols were previ-
ously published [7]. Patients with M1 disease (non-regional 
nodal disease or distant metastases) on PET/CT (n = 6) or 
those with incomplete EUS staging (n = 39) were excluded. 
All patients were staged N0 on PET/CT by a Consultant 
Radiologist certiied in PET/CT reporting and had staging 
EUS completed. All staging was classiied according to the 
TNM 7th edition [9].
The same selection criteria were applied to the validation 
cohort. Patients staged N0 with PET/CT between 1st January 
2013 and 31st June 2015 were considered for the validation 
cohort (n = 166). Patients with distant metastases (n = 4) or 
incomplete EUS staging (n = 23) were excluded. Following 
exclusions, 139 patients were included in the validation study. 
All patients in the validation cohort followed the usual staging 
pathway and had PET/CT in site 2 using the same scanner and 
protocol [7]. All patients had complete EUS staging using the 
same technique as described in the development cohort [7]. 
All staging was classiied according to the TNM 7th edition 
[9]. As in the previous study, 2 variables were recorded for 
each patient: EUS T-stage (T1–4a) and EUS N-stage (N0–3). 
A third variable was derived from the EUS N-stage: EUS N0 
versus N+ (N1, N2 or N3).
Survival data
The primary outcome of the study was OS, deined in months 
from the date of diagnosis. Survival data were updated in July 
2016 ensuring at least 12 months of follow-up per patient. 
Patients were followed-up every 3 months for the irst year, 
then every 6 months thereafter. No patients were lost to 
follow-up.
Statistical analysis
Continuous data were expressed as median (range) and cat-
egorical data as frequency (%). Univariate analysis was per-
formed for EUS T-stage, EUS N-stage, and EUS N0 versus 
N+, and diferences between groups assessed using the log-
rank test [10]. Two Cox regression models were constructed to 
assess the independent prognostic value of variables; model 1 
included EUS T-stage and EUS N-stage and model 2 included 
EUS T-stage and EUS N0 versus N+ [11]. Kaplan–Meier anal-
ysis using the log-rank test assessed diferences in OS between 
the development and validation cohorts. In addition, model 
discrimination was assessed using a log-rank test to evaluate 
OS diferences between pN0 and pN+ groups in the sub-group 
of patients who underwent surgical resection in the valida-
tion cohort. The efect of two diferent PET/CT scanners in 
the development study was further investigated by excluding 
patients from site 1 and re-calculating the models. The event-
per-variable (EPV) ratio ensured that the study was adequately 
powered, with a minimum EPV of 10 recommended, and an 
event deined as a death [12]. A p value of < 0.05 was con-
sidered statistically signiicant. Statistical analysis was per-
formed with SPSS v23 (IBM, Chicago, USA). This validation 
study is reported according to the Transparent Reporting of a 
Multivariable Prediction Model for Individual Prognosis or 
Diagnosis (TRIPOD) guidelines [13].
Results
Patient cohorts
The baseline characteristics of development and validation 
patient cohorts are included in Table 1. There were no 
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missing data in this study. The median age of the devel-
opment and validation cohorts was 67.0  years (range 
24.0–82.0) and 66.0  years (39–84), respectively. The 
median follow-up period was 25.0 months in the develop-
ment cohort (95% CI 23.1–26.9) and 26.0 months (95% 
CI 22.7–29.3) in the validation cohort. Mean survival 
times are presented because a 50% mortality rate was not 
reached in either cohort. The mean OS of the develop-
ment cohort was 33.1 months (95% CI 30.1–36.1) and 
29.8 months (95% CI 27.1–35.2) in the validation cohort.
Summary of results from development cohort
Univariate analysis showed that EUS T-stage (Χ2 8.321, 
df 3, p = 0.040), N-stage (Χ2 14.879, df 3, p = 0.002), 
and N0 versus N+ (χ2 11.325, df 1, p = 0.001) were sig-
niicantly associated with OS. When EUS T-stage and 
N-stage were entered in model 1, only EUS N-stage was 
significantly and independently associated with dura-
tion of survival [hazard ratio (HR) 1.616–4.707, 95% CI 
0.363–7.190, p = 0.005]. When EUS T-stage and EUS N0 
versus N+ were entered in model 2, EUS N0 versus N+ 
Table 1  Baseline characteristics 
of patients in development and 
validation cohorts
Frequency (%) Development cohort (n = 117) Validation cohort (n = 139)
Male:female 88 (75.2):29 (24.8) 108 (77.7):31 (22.3)
Tumour location
 Oesophagus 73 (62.4) 76 (54.7)
  Upper 0 (0.0) 2 (2.7)
  Mid 20 (27.4) 22 (28.9)
  Distal 53 (72.6) 52 (68.4)
 Junction 44 (37.6) 63 (45.3)
  Siewert type I 5 (11.3) 25 (39.7)
  Siewert type II 12 (27.3) 18 (28.6)
  Siewert type III 27 (61.4) 20 (31.7)
 Histology
  Adenocarcinoma 98 (83.8) 107 (77.0)
  SCC 19 (16.2) 26 (18.7)
  HGD 0 (0.0) 3 (2.2)
  Neuro-endocrine 0 (0.0) 2 (1.4)
  Undiferentiated 0 (0.0) 1 (0.7)
 EUS T-stage
  T1 18 (15.4) 20 (14.4)
  T2 16 (13.7) 18 (12.9)
  T3 75 (64.1) 86 (61.9)
  T4a 8 (6.8) 13 (9.4)
  T4b 0 (0.0) 2 (1.4)
EUS N-stage
  N0 78 (66.7) 89 (64.0)
  N1 23 (19.7) 42 (30.2)
  N2 9 (7.6) 7 (5.1)
  N3 7 (6.0) 1 (0.7)
Treatment
 Curative 105 (89.7) 116 (83.5)
  NACT 40 (38.1) 44 (37.9)
  dCRT 29 (27.6) 39 (33.6)
  Surgery alone 32 (30.5) 19 (16.4)
  NACRT 1 (0.9) 11 (9.5)
  EMR 3 (2.9) 3 (2.6)
 Palliative 12 (10.3) 23 (16.5)
 Mortality
  Alive 84 (71.8) 85 (61.2)
  Dead 33 (28.2) 54 (38.8)
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was signiicantly and independently associated with OS 
(HR 3.105, 95% CI 1.543–6.247, p = 0.001).
Univariate analysis in validation cohort
EUS T-stage (χ2 21.031, df 4, p < 0.001) (Fig. 1) and EUS 
N0 versus N+ (χ2 4.300, df 1, p = 0.038) were signiicantly 
associated with OS. EUS N-stage did not show a statis-
tically signiicant association with OS (χ2 5.699, df 3, 
p = 0.127). Table 2 shows mean survival data for patients 
classiied by EUS T-stage, N-stage, and EUS N0 versus 
N+.
Multivariate analysis in validation cohort
Again, two Cox regression models were produced in the 
validation cohort. EUS T-stage and EUS N-stage were 
entered in model 1. EUS T-stage was signiicantly and inde-
pendently associated with OS (HR 11.656–30.114, 95% CI 
0.994–243.079, p = 0.011). (Table 3) The EPV ratio was 
27.0.
EUS T-stage and EUS N0 versus N+ were entered in 
model 2. Again, EUS T-stage was signiicantly and inde-
pendently associated with OS (HR 11.714–29.631, 95% CI 
1.067–238.959, p = 0.012). (Table 4) The EPV ratio was 
27.0.
There was no statistically signiicant diference in OS 
between the development (mean OS 33.0 months, 95% 
CI 30.060–36.076) and validation cohorts (mean OS 29.8 
months, 95% CI 27.120–32.513) (χ2 1.979, df 1, p = 0.159).
Fig. 1  Signiicant diference in cumulative survival by EUS T-stage 
in Validation cohort (χ2 21.031, df 4, p < 0.001). Patients with more 
advanced EUS T-stage have worse OS
Table 2  Survival data of patients in validation cohort derived from 
univariate analysis




 T1 41.563 38.834 44.291
 T2 25.830 20.062 31.598
 T3 27.908 24.484 31.332
 T4a 16.846 9.842 23.851
 T4b 17.500 4.334 30.666
N-stage
 N0 31.853 28.735 34.971
 N1 25.625 21.246 30.004
 N2 16.857 11.873 21.841
 N3 17.000 17.000 17.000
 N+ 24.924 20.966 28.882
Table 3  Results of model 1 multi-variate analysis including EUS 
T-stage and EUS N-stage in validation cohort
Variable p value Hazard ratio df 95% conidence 
interval
Lower Upper
EUS T-stage 0.011 4
 T2 0.018 12.482 1 1.528 101.957
 T3 0.016 11.656 1 1.570 86.548
 T4a 0.001 30.114 1 3.731 243.079
 T4b 0.050 16.270 1 0.994 266.273
EUS N-stage 0.553 3
 N1 0.560 1.192 1 0.660 2.154
 N2 0.353 1.653 1 0.572 4.772
 N3 0.260 3.176 1 0.425 23.716
Table 4  Results of model 2 multi-variate analysis including EUS 
T-stage and EUS N0 versus N+ in validation cohort
Variable p value Hazard ratio df 95% conidence 
interval
Lower Upper
EUS T-stage 0.012 4
 T2 0.020 11.977 1 1.469 97.620
 T3 0.016 11.714 1 1.579 86.902
 T4a 0.001 29.631 1 3.674 238.959
 T4b 0.045 17.243 1 1.067 278.714
EUS N0 vs N+ 0.359 1.292 1 0.747 2.235
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Efect of including site 1 patients in development 
cohort
A post hoc analysis was performed to determine the efect 
of including patients scanned in site 1 on the development 
cohort prognostic models. To perform this post hoc analysis, 
site 1 patients were excluded from the development cohort in 
an attempt to control comparison with the validation cohort. 
Seventy patients were originally scanned at site 2. Of these, 
53 patients (75.7%) were staged EUS N0; 11 (15.7%) were 
EUS N1; 3 (4.3%) were N2, and 3 (4.3%) were N3. Both 
EUS N-stage (HR 2.365–32.757, 95% CI 0.476–223.922, 
p = 0.005) and EUS N0 versus N+ (HR 3.783, 1.141–12.539, 
p = 0.030) were independent predictors of OS, in keeping 
with indings from the original study. Therefore, inclusion 
of site 1 patients had little efect on the prognostic models 
of the development cohort. Conidence intervals are wide, 
likely due to the small numbers in N2 and N3 groups.
Comparison of patient eligibility for development 
and validation cohorts
A comparison of the proportion of patients who were staged 
N0 and considered for inclusion during both study periods 
was made. Post hoc review revealed that 117 of 207 patients 
(56.5%) from site 2 were staged N0 on PET/CT during the 
study recruitment period of the development cohort and 139 
of 317 (43.8%) from site 2 were staged N0 during the study 
recruitment period of the validation cohort. This diference 
was statistically signiicant (χ2 8.049, df 1, p = 0.005). A 
signiicantly higher proportion of patients from site 2 were 
staged N0 in the development cohort, suggesting that dif-
ferent proportions of patients were eligible for inclusion, 
potentially afecting the results of the prognostic models.
Prognostic signiicance of pathological lymph nodes
In total, 74 patients from the validation cohort underwent 
surgical resection. Thirty-nine patients (52.7%) were classi-
ied pN0 and 35 patients (47.3%) were classiied pN+. There 
was a signiicant diference in OS between pN0 and pN+ 
groups (χ2 13.315, df 1, p < 0.001). (Fig. 2) Mean OS for the 
pN0 group was 40.091 months (95% CI 36.931–43.251) and 
26.538 (95% CI 22.123–30.953) for the pN+ group.
Discussion
This validation study failed to replicate the results of the 
developed prognostic model. In the validation cohort, EUS 
N-stage and EUS N0 versus N+ did not show prognostic 
signiicance in multi-variate analysis, although EUS N0 ver-
sus N+ was statistically signiicant in univariate analysis 
(p = 0.038). Relatively small numbers of patients staged 
EUS N2 and N3 were included in the development cohort 
(n = 9 and n = 7, respectively) which could result in dispro-
portionate statistical signiicance and failure to validate this 
variable. Importantly, this study showed that EUS T-stage is 
signiicantly and independently associated with OS, which 
supports other studies [14–16]. The study adds evidence to 
the importance of EUS in the multi-modality approach to 
oesophageal cancer staging.
When patients scanned in site 1 were removed from the 
development cohort, EUS N-stage and EUS N0 versus N+ 
remained independent predictors of OS. This inding sug-
gests that the site 1 PET/CT scanner had little efect on the 
developed prognostic model. One reason for the inability 
to validate the model could be the statistically signiicant 
diference in proportions of patients staged N0 during both 
study periods, resulting in fewer patients from site 2 eligi-
ble for inclusion in the validation study recruitment period 
(those staged N0 on PET/CT).
An important issue in validation studies is the extent to 
which the included cohorts difer. This can result in valida-
tion failure unless appropriately adjusted for [17]. Report-
ing trends over time have not been assessed in this study, 
but reporting and context bias have been shown to inluence 
radiologists image interpretation [18]. It is possible that a 
priori knowledge of key indings from the developed prog-
nostic model may increase the likelihood of equivocal lymph 
nodes on PET/CT being called positive. This awareness of 
having been studied with consequent impact on behaviour, 
the so-called ‘Hawthorne efect’, could have contributed to 
the change in results [19]. However, this is merely a hypoth-
esis and cannot be concluded from these data. In addition, 
Fig. 2  Signiicant diference in cumulative survival depending on the 
presence of pathological lymph nodes (χ2 13.315, df 1, p < 0.001). 
Patients with positive pathological lymph nodes have worse OS
 Surgical Endoscopy
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operators were not fully blinded to the results of the PET/CT, 
potentially inluencing the interpretation of EUS N-stage. 
The inal report of the PET/CT is routinely checked prior 
to EUS to ensure that no distant metastases are detected, 
preventing inappropriate EUS examination.
Prior to the opening of site 2 in 2010, patients were 
scanned at site 1 using a Philips 16 section Gemini GXL 
dedicated PET/CT system (Philips Medical Systems, Cleve-
land, USA). The two sites used diferent scanners and proto-
cols, and patients were scanned at diferent activity uptake 
times. Patients were scanned at 60 min of uptake time in 
site 1 and after 90 min in site 2. Longer uptake times lead 
to higher tumour to background avidity and can therefore 
increase the conspicuity of lymph node metastases. Sec-
ondly, the scanner in site 2 had a time-of-light (TOF) algo-
rithm but the site 1 scanner did not. TOF reconstructions 
improve signal-to-noise ratio, detection and anatomical 
localisation of lymph node metastases by allowing more 
precise measurement of the time diference between detec-
tions [20]. Finally, images were acquired for 4 min per bed 
position in site 1, whereas the acquisition was 3 min per bed 
position in site 2. Some improvement in image quality may 
be expected in site 1 with longer acquisition times, provided 
the patient remained still. However, the results of this valida-
tion study assume that longer acquisition did not afect the 
models. Standardised PET acquisition protocols have been 
discussed in the literature [21], but these indings suggest the 
diferences may be less inluential than previously thought, 
adding generalisability to the results.
An additional hypothesis for the failure of validation is 
the accuracy of the staging investigations. Results from our 
institution have shown suboptimal diagnostic accuracy in 
the general oesophageal cancer population [22]. Overall 
accuracy of diferentiating negative and positive nodal dis-
ease on CT, EUS, and PET/CT was 54.5, 55.4, and 57.1%, 
respectively. Sensitivity and speciicity were 39.7 and 77.3% 
with CT, 42.6 and 75.0% with EUS and 35.3 and 90.9% with 
PET/CT. These results were largely attributable to the detec-
tion of micro-metastases in 44% of lymph nodes (deined 
as ≤ 2 mm) evaluated pathologically. The suboptimal accu-
racy could afect results of the developed prognostic model, 
obtaining a signiicant diference in survival between EUS 
N-stage categories by chance alone.
The additional sub-group analysis conducted in this 
study conirms the presence of lymph node metastases as 
a major prognostic indicator [2]. There was a highly sig-
niicant diference in OS between pN0 and pN+ groups in 
patients staged N0 on PET/CT. This inding highlights the 
importance of accurate pre-treatment lymph node staging in 
oesophageal cancer.
Model validation is not commonly performed in prog-
nostic research. Approximately 34% of models are vali-
dated, with 11% undergoing external validation [23]. The 
importance of rigorous study design and statistical analy-
sis cannot be understated, and further research is required 
to improve prognostic research methodology [24, 25]. In 
addition, it is important to document and publish the ind-
ings of all prognostic research, including ‘non-signiicant’ 
indings, since publication bias is prevalent [26].
This validation study is limited by some factors. Both 
development and validation cohorts represent a relatively 
heterogeneous cohort of patients; however, this is relec-
tive of the demographics of oesophageal cancer patients 
in general. Dissemination of lymph node metastases is 
dependent on T-stage and to a lesser extent, histological 
cell type of the primary tumour [27, 28]. Stratiication of 
these factors was not performed, but most patients pre-
sented with locally advanced T3 or T4 tumours. The EUS 
operators may have been inluenced by results of the PET/
CT reports, resulting in inadvertent changes in lymph node 
assessment over time. In addition, the inclusion of patients 
from site 1 could not be replicated in the validation cohort 
because our patients no longer attend this site for PET/CT.
Despite the limitations, this validation study has sev-
eral strengths. All patients were managed by an experi-
enced Upper gastrointestinal cancer multi-disciplinary 
team covering a population of approximately 1.5 million. 
The site 2 PET/CT scanner and acquisition protocol was 
unchanged in both development and validation cohorts. 
The study was adequately powered according to a recom-
mended EPV ratio. In addition, a pathologist reviewed the 
resected lymph nodes to evaluate and conirm the presence 
of pathological lymph node metastases.
Conclusion
Validation studies are important in prognostic research 
[29]. Lymph node metastases have a signiicant detrimen-
tal efect on OS. This validation study did not replicate the 
results of the developed prognostic model but the contin-
ued beneit of EUS in patients staged N0 with PET/CT 
was demonstrated. EUS remains a valuable component of 
a multi-modality approach to oesophageal cancer staging.
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